Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Nat Genet ; 39(4): 523-8, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17322885

ABSTRACT

Toll-like receptors (TLRs) and members of their signaling pathway are important in the initiation of the innate immune response to a wide variety of pathogens. The adaptor protein Mal (also known as TIRAP), encoded by TIRAP (MIM 606252), mediates downstream signaling of TLR2 and TLR4 (refs. 4-6). We report a case-control study of 6,106 individuals from the UK, Vietnam and several African countries with invasive pneumococcal disease, bacteremia, malaria and tuberculosis. We genotyped 33 SNPs, including rs8177374, which encodes a leucine substitution at Ser180 of Mal. We found that heterozygous carriage of this variant associated independently with all four infectious diseases in the different study populations. Combining the study groups, we found substantial support for a protective effect of S180L heterozygosity against these infectious diseases (N = 6,106; overall P = 9.6 x 10(-8)). We found that the Mal S180L variant attenuated TLR2 signal transduction.


Subject(s)
Bacteremia/genetics , Malaria/genetics , Membrane Transport Proteins/genetics , Myelin Proteins/genetics , Pneumococcal Infections/genetics , Polymorphism, Single Nucleotide , Proteolipids/genetics , Tuberculosis/genetics , Africa , Case-Control Studies , Genetic Predisposition to Disease , Humans , Linkage Disequilibrium , Membrane Glycoproteins/genetics , Membrane Transport Proteins/physiology , Models, Molecular , Myelin Proteins/physiology , Myelin and Lymphocyte-Associated Proteolipid Proteins , Polymorphism, Single Nucleotide/physiology , Proteolipids/physiology , Receptors, Interleukin-1/genetics , Toll-Like Receptor 2/metabolism , Toll-Like Receptor 4/metabolism , United Kingdom , Vietnam
2.
N Engl J Med ; 362(22): 2092-101, 2010 Jun 03.
Article in English | MEDLINE | ID: mdl-20484391

ABSTRACT

BACKGROUND: The interleukin-2-mediated immune response is critical for host defense against infectious pathogens. Cytokine-inducible SRC homology 2 (SH2) domain protein (CISH), a suppressor of cytokine signaling, controls interleukin-2 signaling. METHODS: Using a case-control design, we tested for an association between CISH polymorphisms and susceptibility to major infectious diseases (bacteremia, tuberculosis, and severe malaria) in blood samples from 8402 persons in Gambia, Hong Kong, Kenya, Malawi, and Vietnam. We had previously tested 20 other immune-related genes in one or more of these sample collections. RESULTS: We observed associations between variant alleles of multiple CISH polymorphisms and increased susceptibility to each infectious disease in each of the study populations. When all five single-nucleotide polymorphisms (SNPs) (at positions -639, -292, -163, +1320, and +3415 [all relative to CISH]) within the CISH-associated locus were considered together in a multiple-SNP score, we found an association between CISH genetic variants and susceptibility to bacteremia, malaria, and tuberculosis (P=3.8x10(-11) for all comparisons), with -292 accounting for most of the association signal (P=4.58x10(-7)). Peripheral-blood mononuclear cells obtained from adult subjects carrying the -292 variant, as compared with wild-type cells, showed a muted response to the stimulation of interleukin-2 production--that is, 25 to 40% less CISH expression. CONCLUSIONS: Variants of CISH are associated with susceptibility to diseases caused by diverse infectious pathogens, suggesting that negative regulators of cytokine signaling have a role in immunity against various infectious diseases. The overall risk of one of these infectious diseases was increased by at least 18% among persons carrying the variant CISH alleles.


Subject(s)
Bacteremia/genetics , Genetic Predisposition to Disease , Malaria/genetics , Polymorphism, Single Nucleotide , Suppressor of Cytokine Signaling Proteins/genetics , Tuberculosis/genetics , Adult , Case-Control Studies , Child , Gene Expression , Genotype , Humans , Interleukin-2/physiology , Linkage Disequilibrium , Odds Ratio , Risk , Suppressor of Cytokine Signaling Proteins/metabolism
3.
BMC Infect Dis ; 11: 307, 2011 Nov 03.
Article in English | MEDLINE | ID: mdl-22047086

ABSTRACT

BACKGROUND: Trichomonas vaginalis has been associated with increased vaginal HIV-1 RNA shedding in antiretroviral therapy (ART)-naïve women. The effect of trichomoniasis on vaginal HIV-1 shedding in ART-treated women has not been characterized. We tested the hypothesis that T. vaginalis infection would increase vaginal HIV-1 RNA shedding in women on ART, and that successful treatment would reduce vaginal HIV-1 RNA levels. METHODS: We conducted a prospective cohort study including monthly follow-up of 147 women receiving ART in Mombasa, Kenya. Those with T. vaginalis infection, defined by the presence of motile trichomonads on vaginal saline wet mount, received treatment with single dose metronidazole (2 g). Test of cure was performed at the next monthly visit. Using the pre-infection visit as the reference category, we compared detection of vaginal HIV-1 RNA before versus during and after infection using generalized estimating equations. A cut-off of 100 HIV-1 RNA copies/swab was used as the lower limit for linear quantitation. RESULTS: Among 31 women treated for trichomoniasis, the concentration of vaginal HIV-1 RNA was above the limit for quantitation before, during, and after T. vaginalis infection in 4 (13% [95% CI 4% - 30%]), 4 (13% [95% CI 4% - 30%]), and 5 (16% [95% confidence interval {CI} 5% - 34%]) women respectively. After adjusting for potential confounding factors, we could detect no difference in the likelihood of detecting vaginal HIV-1 RNA before versus during infection (odds ratio [OR] 1.41, 95% CI 0.23 - 8.79, p = 0.7). In addition, detection of HIV-1 RNA was similar before infection versus after successful treatment (OR 0.68, 95% CI (0.13 - 3.45), p = 0.6). CONCLUSION: Detection of vaginal HIV-1 RNA during ART was uncommon at visits before, during and after T. vaginalis infection.


Subject(s)
Anti-HIV Agents/administration & dosage , HIV Infections/complications , HIV-1/isolation & purification , Trichomonas Vaginitis/epidemiology , Trichomonas vaginalis/isolation & purification , Vagina/virology , Virus Shedding , Adolescent , Adult , Antiprotozoal Agents/administration & dosage , Antiretroviral Therapy, Highly Active , Cohort Studies , Female , HIV Infections/drug therapy , Humans , Kenya/epidemiology , Metronidazole/administration & dosage , Middle Aged , Prospective Studies , RNA, Viral/isolation & purification , Trichomonas Vaginitis/parasitology , Viral Load , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL